Helix BioPharma Secures $13 Million Financing to Advance Cancer Therapies

Helix BioPharma ( (TSE:HBP) ) has shared an update.

Helix BioPharma Corp. has signed a capital raising agreement with Kerentech Consulting Ltd. to secure USD 13 million in bridge financing. This funding will support the development of Helix’s lead therapeutic programs, including L-DOS47, which is being developed for non-small cell lung cancer. This collaboration is part of Helix’s strategy to accelerate its clinical development efforts and strengthen its financial position.

Spark’s Take on TSE:HBP Stock

According to Spark, TipRanks’ AI Analyst, TSE:HBP is a Underperform.

Helix BioPharma faces significant financial challenges with no revenue and continuous losses, resulting in a low financial performance score. Weak market momentum and poor valuation metrics further dampen the stock’s attractiveness. Recent corporate events provide some strategic hope, but are not enough to overcome the fundamental financial issues.

To see Spark’s full report on TSE:HBP stock, click here.

More about Helix BioPharma

Helix BioPharma Corp. is a clinical-stage oncology company focused on developing innovative treatments for hard-to-treat cancers. The company’s lead product is Tumor Defense Breaker™ L-DOS47, an antibody-enzyme conjugate targeting CEACAM6-expressing tumors. Helix is also advancing two pre-IND candidates, LEUMUNA™ and GEMCEDA™, aimed at treating leukemia relapse and advanced cancers, respectively.

Average Trading Volume: 3,848

Technical Sentiment Signal: Sell

Current Market Cap: C$50.9M

Find detailed analytics on HBP stock on TipRanks’ Stock Analysis page.